TY  - JOUR 
AU  - Del Pozo, V.
AU  - Bobolea, I.
AU  - Rial Prado, Manuel Jorge
AU  - Espigol-Frigolé, G.
AU  - Solans Laqué, R.
AU  - Hernández-Rivas, J.M.
AU  - Mora, E.
AU  - Crespo-Lessmann, A.
AU  - Izquierdo Alonso, J.L.
AU  - Domínguez Sosa, M.S.
AU  - Maza-Solano, J.
AU  - Atienza-Mateo, B.
AU  - Bañas-Conejero, D.
AU  - Moure, A.L.
AU  - Rúa-Figueroa, Í.
PY  - 2023
SN  - 1664-3224
UR  - http://hdl.handle.net/20.500.11940/21472
AB  - Eosinophil-related diseases represent a group of pathologic conditions with highly heterogeneous clinical presentation and symptoms ranging from mild to critical. Both systemic and localized forms of disease are typically treated with glucocorticoids....
LA  - eng
KW  - Humans
KW  - Glucocorticoids
KW  - Churg-Strauss Syndrome
KW  - Consensus
KW  - Eosinophils
KW  - Granulomatosis with Polyangiitis
KW  - Leukocyte Disorders
KW  - Biological Products
TI  - Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases
DO  - 10.3389/fimmu.2023.1310211
T2  - Frontiers in immunology
M2  - 1310211
KW  - AS A Coruña
KW  - CHUAC
VL  - 14
ER  -